EUVIMEDEUVIMED entdecken
Open Access

An update on clinical presentation and responses to therapy of patients with hereditary hypophosphatemic rickets with hypercalciuria (HHRH)

Zewu Zhu, Bryan Bo-Ran Ho, Alyssa Chen, James Amrhein, Andreea Apetrei, Thomas Oliver Carpenter, Marise Lazaretti-Castro, Juan Manuel Colazo, Kathryn McCrystal Dahir, Michaela Geßner, Evgenia Gurevich, Cathrine Alsaker Heier und 16 weitere

Kidney International · 2024

DOI: 10.1016/j.kint.2024.01.031 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Kidney International, 2024. Verfasst von Zewu Zhu und 27 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Section of Endocrinology, Yale University School of Medicine, New Haven, Connecticut, USA; Department of Urology, Xi…. Hauptthemen laut MEDLINE: Familial Hypophosphatemic Rickets, Hypophosphatemia. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 88 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAMS NIH HHS, NCATS NIH HHS, Central South University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pathogenic variants in solute carrier family 34, member 3 (SLC34A3), the gene encoding the sodium-dependent phosphate cotransporter 2c (NPT2c), cause hereditary hypophosphatemic rickets with hypercalciuria (HHRH). Here, we report a pooled analysis of clinical and laboratory records of 304 individuals from 145 kindreds, including 20 previously unreported HHRH kindreds, in which two novel SLC34A3 pathogenic variants were identified. Compound heterozygous/homozygous carriers show above 90% penetrance for kidney and bone phenotypes. The biochemical phenotype for heterozygous carriers is intermediate with decreased serum phosphate, tubular reabsorption of phosphate (TRP (%)), fibroblast growth factor 23, and intact parathyroid hormone, but increased serum 1,25-dihydroxy vitamin D, and urine calcium excretion causing idiopathic hypercalciuria in 38%, with bone phenotypes still observed in 23% of patients. Oral phosphate supplementation is the current standard of care, which typically normalizes serum phosphate. However, although in more than half of individuals this therapy achieves correction of hypophosphatemia it fails to resolve the other outcomes. The American College of Medical Genetics and Genomics score correlated with functional analysis of frequent SLC34A3 pathogenic variants in vitro and baseline disease severity. The number of mutant alleles and baseline TRP (%) were identified as predictors for kidney and bone phenotypes, baseline TRP (%) furthermore predicted response to therapy. Certain SLC34A3/NPT2c pathogenic variants can be identified with partial responses to therapy, whereas with some overlap, others present only with kidney phenotypes and a third group present only with bone phenotypes. Thus, our report highlights important novel clinical aspects of HHRH and heterozygous carriers, raises awareness to this rare group of disorders and can be a foundation for future studies urgently needed to guide therapy of HHRH.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Familial Hypophosphatemic RicketsHypophosphatemiaHumansHypercalciuriaKidneyPhosphatesSodium-Phosphate Cotransporter Proteins, Type IIc

Stichwörter der Autor:innen

HHRHSLC34A3phosphate therapyrenal calcifications

Substanzen

PhosphatesSodium-Phosphate Cotransporter Proteins, Type IIc

Autor:innen und Institutionen

  • Department of Internal Medicine, Section of Endocrinology, Yale University School of Medicine, New Haven, Connecticut, USA; Department of Urology, Xiangya Hospital, Central South University, Changsha, Hunan, China.
  • Department of Internal Medicine, Section of Endocrinology, Yale University School of Medicine, New Haven, Connecticut, USA.
  • Department of Internal Medicine, Section of Endocrinology, Yale University School of Medicine, New Haven, Connecticut, USA; Department of Otolaryngology, Harvard Medical School, Boston, Massachusetts, USA.
  • Pediatric Endocrinology and Diabetes, School of Medicine Greenville Campus, University of South Carolina, Greenville, South Carolina, USA.
  • Caen University Hospital, Department of Genetics, UR7450 Biotargen, Reference Center for Rare Diseases of Calcium and Phosphate Metabolism, OSCAR Network, Caen, France.
  • Division of Endocrinology, Escola Paulista de Medicina-Universidade Federal de Sao Paulo (EPM-UNIFESP), Sao Paulo, Brazil.

Förderung

  • NIAMS NIH HHS
  • NCATS NIH HHS
  • Central South University
  • NIH
  • Instituto de Salud Carlos III
  • European Commission
  • National Center for Advancing Translational Sciences

Zitieren

APA

Zhu, Z., Bo-Ran Ho, B., Chen, A., Amrhein, J., Apetrei, A., Carpenter, T. O., Lazaretti-Castro, M., Colazo, J. M., McCrystal Dahir, K., Geßner, M., Gurevich, E., Heier, C. A., Simmons, J. H., Hunley, T. E., Hoppe, B., Jacobsen, C., Kouri, A., Ma, N., Majumdar, S., …, & Bergwitz, C. (2024). An update on clinical presentation and responses to therapy of patients with hereditary hypophosphatemic rickets with hypercalciuria (HHRH). Kidney International. https://doi.org/10.1016/j.kint.2024.01.031

Vancouver

Zhu Z, Bo-Ran Ho B, Chen A, Amrhein J, Apetrei A, Carpenter TO, et al. An update on clinical presentation and responses to therapy of patients with hereditary hypophosphatemic rickets with hypercalciuria (HHRH). Kidney International. 2024. doi:10.1016/j.kint.2024.01.031

BibTeX
@article{Zhu2024,
  author = {Zhu, Zewu and Bo-Ran Ho, Bryan and Chen, Alyssa and Amrhein, James and Apetrei, Andreea and Carpenter, Thomas Oliver and Lazaretti-Castro, Marise and Colazo, Juan Manuel and McCrystal Dahir, Kathryn and Geßner, Michaela and Gurevich, Evgenia and Heier, Cathrine Alsaker and Simmons, Jill Hickman and Hunley, Tracy Earl and Hoppe, Bernd and Jacobsen, Christina and Kouri, Anne and Ma, Nina and Majumdar, Sachin and Molin, Arnaud and Nokoff, Natalie and Ott, Susan M and Peña, Helena Gil and Santos, Fernando and Tebben, Peter and Topor, Lisa Swartz and Deng, Yanhong and Bergwitz, Clemens},
  title = {An update on clinical presentation and responses to therapy of patients with hereditary hypophosphatemic rickets with hypercalciuria (HHRH)},
  journal = {Kidney International},
  year = {2024},
  doi = {10.1016/j.kint.2024.01.031}
}
Kostenlos starten →